Northwest's DCVax-L Adds UK Sites in Phase III GBM Program
The Medicines and Healthcare Products Regulatory Agency of the UK approved a 300-patient Phase III trial of Northwest Biotherapeutics Inc.'s DCVax-L for glioblastoma multiforme (GBM). Phase III is in full swing in the U.S., at 41 clinical sites, but Northwest seeks to expand the trial to international sites, starting in the UK, stating it will save several years' time by not carrying out separate U.S. and European trials.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter